Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: BLLN

BillionToOne, Inc.

Healthcare | Medical - Diagnostics & Research

No licensed closing price on file for BLLN. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

BillionToOne, Inc. (NASDAQ: BLLN) is a diagnostics and research company. Figures from SEC EDGAR; updated 2026-10-20 04:32 UTC.

What BillionToOne, Inc. does

BillionToOne is a molecular diagnostics company that uses single-molecule next-generation sequencing technology to detect genetic targets in cell-free DNA from blood samples. The company's patented technology platform enables measurements at the single DNA molecule level, which traditional sequencing methods cannot achieve. BillionToOne has developed prenatal and oncology products, including UNITY for prenatal genetic risk assessment and Northstar Select and Northstar Response for cancer detection and monitoring.

Summarized from BillionToOne, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
Return on equity1.55%
Debt/equity0.17

Revenue, margins & earnings

FY2023: net loss $83M on revenue $72M$72MFY2023FY2024: net loss $42M on revenue $153M$153MFY2024FY2025 Net income: $7MFY2025 Taxes & interest: $9MFY2025 Operating expenses: $192MFY2025 Cost of revenue: $97M$305MFY2025
  • Net income
  • Taxes & interest
  • Operating expenses
  • Cost of revenue
  • Net loss year
Annual revenue; bands show net, operating, gross margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-16
  • 2026-10-16Chairman and CEOSale-3,083$303.1K
  • 2026-10-16Chairman and CEOSale-980$99.8K
  • 2026-10-16Chairman and CEOSale-133$13.7K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does BillionToOne, Inc. do?

BillionToOne is a molecular diagnostics company that uses single-molecule next-generation sequencing technology to detect genetic targets in cell-free DNA from blood samples.

When did BLLN last file with the SEC?

BillionToOne, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-29. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 04:32 UTC. This page is also available as JSON at /api/data?ticker=BLLN and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for BLLN and 5,000+ tickers.

Create a free account — keep BLLN
For your agent
GET /api/data?ticker=BLLN

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt